Clinical bottom line
Acute severe croup in pediatric patients is a common cause of upper airway obstruction requiring timely assessment and management in primary care settings. Evidence supports the use of corticosteroids as first-line therapy to reduce airway inflammation and improve symptoms. Nebulized epinephrine may be indicated for children with significant respiratory distress or stridor at rest, providing rapid but transient relief. Close monitoring and appropriate referral criteria are essential to ensure safety. Emerging data suggest that viral variants, such as Omicron, may influence disease severity, underscoring the need for vigilance in clinical assessment (Scribner et al., 2022; Retzke et al., 2021).
What the evidence shows
Croup, or acute laryngotracheobronchitis, is primarily a viral illness causing inflammation of the upper airway, leading to characteristic barking cough, stridor, and respiratory distress. The cornerstone of treatment in primary care is corticosteroids, which have demonstrated efficacy in reducing symptom severity, hospital admissions, and the need for additional interventions (Retzke et al., 2021). Single-dose oral dexamethasone is widely recommended due to its long half-life and ease of administration.
Nebulized epinephrine is reserved for children presenting with moderate to severe respiratory distress or stridor at rest. It acts rapidly by vasoconstriction, reducing airway edema, but its effects are short-lived, necessitating observation for potential rebound symptoms (Retzke et al., 2021). The evidence supports its use as a temporizing measure while corticosteroids take effect.
Recent observational data indicate that croup presentations associated with the SARS-CoV-2 Omicron variant may be more severe than typical viral croup, with increased rates of hospitalization and respiratory support (Scribner et al., 2022). This finding highlights the importance of considering viral etiology and local epidemiology in clinical decision-making.
Integrated pediatric primary care models emphasize the role of care management and coordination to optimize outcomes for children with acute severe illnesses, including croup, by facilitating timely access to care and follow-up (Lancaster et al., 2024).
Caveats and uncertainty
While corticosteroids and nebulized epinephrine are well-supported treatments, there remains variability in dosing regimens and timing, reflecting gaps in high-quality randomized controlled trials specifically targeting severe croup in primary care. Most evidence derives from emergency or inpatient settings, which may limit direct applicability.
The impact of emerging viral variants on croup severity and response to treatment is an evolving area. The data on Omicron-associated croup are preliminary and observational, warranting cautious interpretation and further study (Scribner et al., 2022).
Additionally, clinical assessment tools for severity grading vary, and there is no universally accepted standard for risk stratification in primary care, which may affect treatment decisions and referral thresholds.
How this may change practice
Primary care clinicians should maintain a high index of suspicion for severe croup in children presenting with stridor at rest, respiratory distress, or hypoxia. Early administration of corticosteroids remains the mainstay of treatment and should be initiated promptly.
Nebulized epinephrine should be available for use in cases of moderate to severe symptoms but requires appropriate monitoring and readiness to escalate care if symptoms persist or worsen.
Awareness of the potential for more severe disease associated with certain viral variants, such as Omicron, may prompt clinicians to adopt a lower threshold for referral or observation in these contexts.
Implementing integrated care management approaches may improve follow-up and reduce complications by ensuring coordinated care pathways for children with acute severe croup.